ascopubs.org

Classification and Personalized Prognostic Assessment on the Basis of Clinical and Genomic Features in Myelodysplastic Syndromes

Simplified Geriatric Assessment in Older Patients With Diffuse Large B-Cell Lymphoma: The Prospective Elderly Project of the Fondazione Italiana Linfomi We retrospectively enrolled 2,043 patients.
Business Wire

Research and Markets: A Myelodysplastic Syndrome Therapeutics Pipeline Assessment Report - The MDS Therapeutics Market is Forecast to Show Moderate Growth until 2017

DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/f8da06/myelodysplastic_sy) has announced the addition of GlobalData's new ...
Nature

Management of patients with lower-risk myelodysplastic syndromes

Myelodysplastic syndromes (MDS) comprise a heterogeneous group of hematopoietic stem and progenitor cell disorders characterized by ineffective hematopoiesis leading to dysplasia, cytopenias, and an ...
The American Journal of Managed Care

Assessing Treatment Goals for Patients with MDS

Drs Zeidan and Fazal share their opinions on setting appropriate goals for treatment of patients with MDS. Ryan Haumschild, PharmD, MS, MBA: Let’s talk a little more about the management of ...
Healthline

Your Guide to Navigating Myelodysplastic Syndromes Clinical Trials

Myelodysplastic syndromes (MDS) are treated based on type and risk assessment, but traditional therapies may not work for everyone. Clinical trials offer a way to explore emerging treatments and ...
Nature

Refinement of the international prognostic scoring system (IPSS) by including LDH as an additional prognostic variable to improve risk assessment in patients with primary ...

A total of 1247 patients with MDS, who were diagnosed between 1975 and 2002, were included in a joint database of the Austrian–German working group and examined in a retrospective manner. Of these ...